COVID-19 is an emerging, rapidly evolving situation.
NIAID launches China-US research collaboration to fight drug-resistant tuberculosis
April 2010 | Volume 9, Issue 2
Photo courtesy of the U.S. Embassy in China
NIAID Principal Deputy Director Hugh
Auchincloss, M.D., addresses the audience
at the opening of the first study of the
Sino-U.S. (Henan) Tuberculosis Prevention
and Treatment Research Institute. Karyl
Barron, M.D., deputy director of the NIAID
Division of Intramural Research looks on.
On March 11, 2010, NIAID and its partner, the Henan Provincial Health Bureau, launched the first study of the Sino-U.S. (Henan) Tuberculosis Prevention and Treatment Research Institute at the Henan Provincial Chest Hospital in Zhengzhou, China. The institute aims to develop new and improved ways to diagnose, treat, and prevent multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (TB). The research will be conducted by investigators from NIAID, the Henan Provincial Chest Hospital and Fudan University in Shanghai. The institute’s first patient was enrolled into a natural history study the same day.
The emergence of drug-resistant TB is a major health issue globally and an increasing concern in China. The World Health Organization estimates that almost half of all reported cases of MDR TB in 2008 occurred in China and India, with both countries reporting approximately 100,000 new cases each year.
An NIAID delegation joined U.S. Ambassador to China Jon Huntsman and HHS Health Attaché Elizabeth Yuan; representatives from the U.S. Centers for Disease Control and Prevention, Henan Provincial Health Bureau, and Henan Provincial Chest Hospital; and members of the public to commemorate the opening.
To view Adobe PDF files,
download current, free accessible plug-ins from Adobe's website.
Related World Regions / Countries